<DOC>
	<DOC>NCT01496677</DOC>
	<brief_summary>To compare the pharmacokinetic (PK) profile of TR-700 in elderly subjects versus younger control subjects</brief_summary>
	<brief_title>Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects</brief_title>
	<detailed_description>This is an open-label Phase 1 study of a single oral tablet of TR-701 FA 200 mg to compare the TR-700 PK profile in elderly subjects (age 65 years and older, with at least 5 subjects 75 years old or older) and younger control subjects (age 18 to 45 years).</detailed_description>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Male or female subjects in the following groups: An elderly subject at least 65 years of age. At least 5 subjects must be at least 75 years of age OR A matchedcontrol subject between 18 and 45 years of age, inclusive BMI ≥18.0 kg/m2 and ≤35.0 kg/m2 Elderly Group Medical history, physical examination, and laboratory results consistent with stable health (as determined by the Investigator) Control Group Medically stable with no clinically significant abnormalities Significant, uncontrolled, or lifethreatening condition or organ or system condition or disease (eg, impaired cognitive status, respiratory insufficiency, advanced malnutrition) Positive hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus antibody test result Previous inclusion in a TR701 FA or TR701 clinical study ECG finding of QTc interval &gt;500 msec, or other clinically significant ECG abnormality at Screening Female subjects whom are pregnant, lactating or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>volunteer</keyword>
</DOC>